Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 12/20 | 0.61 |
| ▸ | MMP1 | P03956 | 10/20 | 0.61 |
| ▸ | MMP13 | P45452 | 9/20 | 0.61 |
| ▸ | MMP2 | P08253 | 8/20 | 0.61 |
| ▸ | MMP7 | P09237 | 8/20 | 0.57 |
| ▸ | MMP8 | P22894 | 6/20 | 0.56 |
| ▸ | MMP9 | P14780 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219546 | 0.82 | MMP1 (0.63) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7163700 | 0.79 | MMP1 (0.58) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7166258 | 0.79 | MMP1 (0.58) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7163665 | 0.79 | MMP1 (0.58) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7163437 | 0.79 | MMP1 (0.58) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL6666886 | 0.77 | MMP1 (0.56) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7219734 | 0.77 | MMP1 (0.63) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL6765824 | 0.76 | MMP1 (0.82) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL7219446 | 0.74 | MMP3 (0.52) | MMP3MMP1MMP13MMP2MMP7 | |
| SCHEMBL6162727 | 0.73 | MMP1 (0.51) | MMP3MMP1MMP13MMP2MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | claimed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | claimed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | claimed |
| US-6559142-B2 | Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis | WARNER-LAMBERT COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2002-11-14 | — | — | US | disclosed |
| EP-1233017-A1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169160-A1 | Sulfonamide matrix metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP3 3/4885MMP1 4/4885MMP13 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.